Professor
Director, Clinical Chemistry
Director, Core Laboratories, GCRC
1979, Ph.D, City University of New York
Phone: (504) 988-5799
Fax: (504) 988-7389
Teaching:
Clinical pathology; General laboratory medicine; Endocrinology; Clinical outcome research and management; Lipid biochemistry; Signal transduction; Lipid second messengers; Neural networks genomics and proteomics. Dr Clejan was a Fulbright Scholar (Romania) January-July 2002.
Grant Support:
NIH-GCRC, NASA
- Enmon RM, O'Connor KC, Lacks DJ, Schwartz and Clejan S. Dynamics of spheroid self-assembly in liquid-overlay culture of DU-145 human prostate cancer cells. Biotech. Bioeng 18:688-695, 2000.
- Dash S, Kalkeri G, McClure HM, Garry RF, Clejan S, Thung S and Murthy K. Transmission of HCV to a chimpanzee using virus particles produced in an RNA-transfected HepG2 cell culture. J Med Virol 65:276-81, 2001.
- L.A. Kaplan, J.F. Chapman, J.L. Brock, E. Santa Maria, S. Clejan, et al. Prediction of Respiratory Distress Syndrome Using the Abbott FLM-II Amniotic Fluid Assay. Clinica Chimica Acta 326:61-68, 2002.
- S. Clejan, S. Japa, C.Clementson, S.S. Hasabnis, O. David & J. Talano. Blood Histamine is Associated with Coronary Artery Disease, Cardiac Events and Severity of Inflammation and Atherosclerosis. J. Cell Mol Med. 6(4):583-592, 2002.
- Burrow ME, Weldon CB, Collis-Burrow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S, Beckman BS. Cross-talk between phosphatidylinositol-3 kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem 275:9628-9635, 2000.
- Clejan S, O'Connor K, Rosensweig N. Tri-dimensional Prostate Cell Cultures in Simulated Microgravity and Induced Changes in Lipid Second Messengers and Signal Transduction. J Cell Mol Med, 5:1;60-73, 2001.
Ongoing Projects or Activities
Dr. Clejan's laboratory participates in two areas of basic research: prostate cancer and signal transduction. In prostate cancer Dr. Clejan leads a group off scientists as Chair of Prostate Cancer Tasks Force in screening, molecular alterations of p53 gene and metastatic potential and retransformation of prostate tumor cells grown three dimensionally as spheroids. The model of spheroid-bilayer under microgravity is used also for therapeutic drug research in prostate cancer. In signal transduction the laboratory works mainly on lipid second messengers, phospholipases and sphingomyelinases in various hematopoietic cells exposed to erythropoietin and electromagnetic fields. Dr. Clejan is also active in international research on evidence based medical education and web as a tool for medical and postdoctoral education.
Dr. Clejan's laboratory participates in two areas of basic research: prostate cancer and signal transduction. In prostate cancer Dr. Clejan leads a group off scientists as Chair of Prostate Cancer Tasks Force in screening, molecular alterations of p53 gene and metastatic potential and retransformation of prostate tumor cells grown three dimensionally as spheroids. The model of spheroid-bilayer under microgravity is used also for therapeutic drug research in prostate cancer. In signal transduction the laboratory works mainly on lipid second messengers, phospholipases and sphingomyelinases in various hematopoietic cells exposed to erythropoietin and electromagnetic fields. Dr. Clejan is also active in international research on evidence based medical education and web as a tool for medical and postdoctoral education.
Department of Pathology & Laboratory Medicine
Rev DDO 7/04